Literature DB >> 2827750

Electronic spectroscopy of cobalt angiotensin converting enzyme and its inhibitor complexes.

R Bicknell1, B Holmquist, F S Lee, M T Martin, J F Riordan.   

Abstract

Zinc, the catalytically essential metal of angiotensin converting enzyme (ACE), has been replaced by cobalt(II) to give an active, chromophoric enzyme that is spectroscopically responsive to inhibitor binding. Visible absorption spectroscopy and magnetic circular dichroic spectropolarimetry have been used to characterize the catalytic metal binding site in both the cobalt enzyme and in several enzyme-inhibitor complexes. The visible absorption spectrum of cobalt ACE exhibits a single broad maximum (525 nm) of relatively low absorptivity (epsilon = 75 M-1 cm-1). In contrast, the spectra of enzyme-inhibitor complexes display more clearly defined maxima at longer wavelengths (525-637 nm) and of markedly higher absorptivities (130-560 M-1 cm-1). The large spectral response indicates that changes in the cobalt ion coordination sphere occur on inhibitor binding. Magnetic circular dichroic spectropolarimetry has shown that the metal coordination geometry in the inhibitor complexes is tetrahedral and of higher symmetry than in cobalt ACE alone. The presence of sulfur----cobalt charge-transfer bands in both the visible absorption and magnetic circular dichroic spectra of the cobalt ACE-Captopril complex confirm direct ligation of the thiol group of the inhibitor to the active-site metal.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2827750     DOI: 10.1021/bi00397a014

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  2 in total

1.  Spontaneous solubilization of membrane-bound human testis angiotensin-converting enzyme expressed in Chinese hamster ovary cells.

Authors:  M R Ehlers; Y N Chen; J F Riordan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

2.  Inhibition of endothelial-bound angiotensin converting enzyme, in vivo.

Authors:  J D Catravas; J W Ryan; A Y Chung; N E Quinn; B L Anthony
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.